TY - JOUR
T1 - Prevention of Breast Cancer-Related Lymphedema
AU - McEvoy, Maureen P.
AU - Ravetch, Ethan
AU - Patel, Gunj
AU - Fox, Jana
AU - Feldman, Sheldon
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/4
Y1 - 2021/4
N2 - Tremendous progress has been made over the past several decades in the treatment of breast cancer. Mortality and recurrence rates continue to decline. Our ability to tailor patient- and tumor-specific treatments has rapidly advanced. The vast majority of our patients can safely have breast conservation. Unfortunately, for many patients, survivorship is burdened by ongoing quality-of-life issues. Most breast cancer patients are asymptomatic at presentation, and the onus is on us to preserve this. Surgery, radiation, and systemic therapy can result in long-term toxicities that can be amplified with multimodality approaches. We must strive to apply minimally effective therapies rather than a maximally tolerated approach. Breast cancer-related lymphedema (BCRL) is a particularly dreaded chronic complication. This review strives to give the reader a better understanding of BCRL and shed light on wisely choosing an integration of treatment modalities that minimizes BCRL risk. Key literature on emerging concepts is highlighted.
AB - Tremendous progress has been made over the past several decades in the treatment of breast cancer. Mortality and recurrence rates continue to decline. Our ability to tailor patient- and tumor-specific treatments has rapidly advanced. The vast majority of our patients can safely have breast conservation. Unfortunately, for many patients, survivorship is burdened by ongoing quality-of-life issues. Most breast cancer patients are asymptomatic at presentation, and the onus is on us to preserve this. Surgery, radiation, and systemic therapy can result in long-term toxicities that can be amplified with multimodality approaches. We must strive to apply minimally effective therapies rather than a maximally tolerated approach. Breast cancer-related lymphedema (BCRL) is a particularly dreaded chronic complication. This review strives to give the reader a better understanding of BCRL and shed light on wisely choosing an integration of treatment modalities that minimizes BCRL risk. Key literature on emerging concepts is highlighted.
KW - Axillary reverse mapping
KW - De-escalating axillary surgery
KW - Lympha
KW - Lymphedema
KW - Smarter axilary staging
UR - http://www.scopus.com/inward/record.url?scp=85103137791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103137791&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2021.02.009
DO - 10.1016/j.clbc.2021.02.009
M3 - Article
C2 - 33771439
AN - SCOPUS:85103137791
SN - 1526-8209
VL - 21
SP - 128
EP - 142
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 2
ER -